A Small Win in Cutting Drug Costs

The White House plans to reveal a new deal with Regeneron Pharmaceuticals on pricing for their drugs. This move comes after the company was one of the few chosen to negotiate. Regeneron, which makes treatments like the Covid-19 antibody combo, didn’t comment right away. Their stock price jumped over 2% when markets opened.The deal is part of a bigger push to lower drug costs in the U. S. , where prices are some of the highest in the world. Many other drugmakers were asked to join, but only a few agreed. This raises questions about how effective such deals can be without wider participation. Critics argue voluntary deals don’t force enough change. Others wonder if this is just a small step when bigger reforms are needed. Either way, it’s a rare case where a pharmaceutical company is working with the government to address affordability. What happens next could set a pattern for other drugmakers.